OCA
FATE icon

Octagon Capital Advisors’s Fate Therapeutics FATE Stock Holding History

Octagon Capital Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-520,800
Closed -$1.71M – 48
2024
Q2 		$1.71M Hold
520,800
– – 0.27% 40
2024
Q1 		$3.82M Buy
+520,800
New +$3.22M 0.46% 41
2022
Q4 		– Sell
-331,096
Closed -$7.42M – 39
2022
Q3 		$7.42M Buy
+331,096
New +$9.57M 1.28% 20

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Octagon Capital Advisors's FATE Position: Q3 2024 in Review

Octagon Capital Advisors sold out of Fate Therapeutics (FATE) in Q3 2024, closing a stake of 520,800 shares — an estimated $1.71M sold.

Octagon Capital Advisors first reported a position in FATE in Q3 2022 and held it in 3 quarters. The position peaked at $7.42M in Q3 2022. 164 funds tracked by Wall St. Rank hold FATE as of Q3 2024.

  • Octagon Capital Advisors reported no remaining Fate Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 520,800 Fate Therapeutics shares in Q3 2024, an estimated $1.71M.
  • Octagon Capital Advisors first reported a position in Fate Therapeutics in Q3 2022 and held it in 3 quarters.
  • Octagon Capital Advisors's Fate Therapeutics position peaked at $7.42M in Q3 2022.
  • 164 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2024.

Based on Octagon Capital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.